Purpose: To look at the presenting features, Enneking stage, size of primary tumour, method of treatment and patient and doctor delays in upper extremity Ewing's sarcoma to observe the effects on local recurrence, metastasis and survival. Patients and methods: Nineteen patients with upper extremity Ewing's sarcoma were identified using the Scottish Bone Tumour Registry over the past 40 years. Results: With increasing tumour Enneking stage at presentation there was a significantly higher mortality (P ¼ 0.02). Patients with a higher Enneking stage also had an increased trend towards local recurrence (P ¼ 0.08). Stage did not influence the occurrence of metastasis. Patients with larger tumours tended to have a higher mortality (50 vs. 27% dead at 5 years). All patients presented clinically with pain and all but two complained of some sort of swelling. There was a trend towards a higher Enneking Stage in patients presenting with a longer duration of symptoms (P ¼ 0.1). No difference in survival was noted between patients undergoing surgery and chemotherapy and patients undergoing radiotherapy and chemotherapy. Disease-free survival was 100% at both 5 and 10 years for Enneking stage IIA, 56% at 5 and 10 years for stage IIB and 0% at 5 years for stage III. Discussion: This study re-emphasises the potential importance of a diagnostic delay on outcome. Longer symptom duration is associated with a higher Enneking stage at presentation. In turn a higher presenting stage results in a higher mortality. Pain and swelling are prominent clinical findings at first presentation in upper extremity Ewing's.
Introduction
Ewing's sarcoma is a rare malignant tumour occurring primarily in bone but also not uncommonly in soft tissue. Presenting mainly in the second decade of life it has a predilection for the pelvis, the ribs and the diaphyses of long bones. At the time of presentation, approximately 25% of people have radiological metastases. Prior to chemotherapy the relapse rate was approaching 80%, suggesting systemic spread for many people at the time of diagnosis. The treatment of Ewing's sarcoma currently involves a multidisciplinary approach. The use of four-agent chemotherapy has revolutionised the prognosis in Ewing's sarcoma, [1, 2] but some debate still remains as to whether radiotherapy or surgery for localised lesions is superior in terms of survival [3] [4] [5] [6] [7] .
In the upper extremity, the effects of surgery may have far-reaching consequences in terms of function of the upper limb and hand, particularly in the case of amputation. While there is an increased risk of second malignancy with radiotherapy, [8, 9] it has a less disabling impact on function compared to surgery. If there is no survival advantage with surgery for patients developing tumours in the upper extremity then it may be more appropriate to recommend radiotherapy as an adjunct to chemotherapy. In this study the Scottish experience of the presentation and treatment of Ewing's sarcoma in the upper extremity over the last 40 years was analysed to see if any recommendations could be made regarding the most appropriate treatment modalities for these patients.
Analysis was made of the presenting features, Enneking stage [10] size of primary tumour and patient and doctor delays to observe the effects on local recurrence, metastasis and survival.
Patients and methods
The Scottish Bone Tumour Registry is a clinical, pathological and radiological database on the The chi-square test was used for statistical analysis. The significance level was set at P < 0.05. KaplanMeier statistics were used to calculate survival data.
Results
Nineteen cases of upper limb Ewing sarcoma were identified from the database, 14 of whom were male and five of whom were female. Their ages ranged from 3 to 57 years, with a mean age of 19 years. Review of the histology confirmed that the recorded diagnosis of Ewing's sarcoma on the database was correct in each case. Details of patient demographics, presenting symptoms, tumour site and follow up can be seen in table 1.
Time from symptom onset to first doctor appointmentpatient delay Patient delay varied from 1 to 180 months with a median of 6 months. When the patient delay was compared with Enneking stage at presentation there was a trend towards a higher stage at presentation with longer symptoms (P ¼ 0.1).
Time from first doctor appointment to definitive diagnosis -doctor delay Doctor delay varied from 1 to 128 weeks with a median of 5 weeks.
Radiographic features
Original radiographic images were available for analysis in 17 of the patients. Eleven patients had tumours which were less than 80 mm in maximum dimension, while six had tumours of greater size than this. Patients with larger tumours tended to have a higher mortality (50 vs. 27% dead at 5 years).
Treatment

Chemotherapy
Sixteen of the 19 patients underwent neoadjuvant chemotherapy (table 2) .
Two others, who were treated in 1965 and 1971, had only radiotherapy for their tumours. Ten patients had four-agent chemotherapy, while six had three-agent chemotherapy. One other patient was given single-agent chemotherapy for palliative purposes.
Radiotherapy
Fifteen of the 19 patients were treated with radiotherapy. Nine had their therapy as part of the primary treatment, while six others underwent radiotherapy for palliative purposes only. All primary radiotherapy treatments were of high dose (45-60 Gy). There were no cases of second malignancies reported in the registry, although one patient was lost to follow-up when he moved back to Africa.
Surgery
Twelve of the 19 patients underwent surgery. Fifteen procedures were carried out in total, and in 10 instances this was performed as part of the primary tumour treatment.
Following inadequate resection margins in three patients, further surgery was performed with two forequarter amputations and a wide local excision of residual clavicle. A forearm amputation was performed palliatively in one patient who had not undergone any primary surgical treatment and one further patient underwent a thoracic laminectomy to palliate spinal metastasis.
Chemotherapy and surgery
Five cases were identified where chemotherapy and surgery were the primary treatment modalities. One was Enneking stage IIA, while the other four 
Enneking stage at presentation versus metastasis, survival and local recurrence
The Enneking stage at presentation did not appear to be related to the presence of clinically identifiable metastasis. Higher Enneking stage at presentation was, however, associated with a significantly greater mortality (P ¼ 0.02). With regard to local recurrence following treatment, there was a trend towards local recurrence in higher stage tumours (P ¼ 0.08).
Disease-free survival
Ten-year disease-free survival was 100% for patients with Enneking stage IIA disease and 56% with IIB disease. For stage III disease there were no survivors.
Discussion
Despite being the second most common primary bone tumour, Ewing's sarcoma is still rare. Its annual incidence is approximately 0.8 per million population [11] . Even specialist oncological surgeons may see only a handful of cases. Ewing's of the upper extremity is seen even less frequently. This poses particular problems when it comes to identifying patients with a tumour and subsequently deciding the most appropriate management. Previous studies have looked at the presenting symptoms and clinical features of Ewing sarcoma based on data collected at the oncology clinic when a diagnosis was either suspected or confirmed [12, 13] . Widhe et al. [14] looked at the presenting symptoms and clinical features of Ewing from the first visit to a physician but none of the patients in their series of 48 had a tumour of the upper extremity. In this series, details of the presenting complaints and physical findings found on the first physician visit were also available, so a direct comparison of presenting features was possible between patients with upper extremity Ewing and patients with tumours in other anatomical areas.
In this study tumours occurred almost 3 times as often in males when compared to females, and the mean age was 19 years. These findings concur with previous large studies of Ewing sarcoma. [15, 16] All patients presented with pain, and 17 of the 19 (84%) complained of a mass which was palpable on examination. This is greater than the experience of other studies and may be explained by the relative lack of soft tissue coverage in the upper limb. Night pain, which is frequently considered a hallmark of a bone malignancy, was uncommon, occurring in only 26% of cases. The absence of night pain therefore should not be a reassuring feature.
The two patients who complained of neurological symptoms both died and were found to have Enneking stage III tumours at diagnosis. This is, perhaps, not surprising, with features of neural invasion in most tumours also frequently heralding a poor prognosis.
The median diagnostic delay for this series was 35 weeks which is very similar to other published series [14, 17, 18] . The vast majority of this delay was due to patient factors (30 weeks) and may have occurred due to the intermittent nature of the symptoms described (52% of patients) or the fact that symptom onset was associated with trauma (37% of patients). In one case the doctor-associated delay was particularly prolonged due to an incorrect diagnosis of osteomyelitis being given. This unfortunate pitfall has been described previously. [19] The tendency of patients with Ewing's tumour to have symptoms and signs of sepsis and the necessity for submission of material from any case of suspected bone infection for histology as well as culture cannot be overstated.
The length of symptom duration did not affect the presenting Enneking stage significantly, although it was found that in those who presented with tumours of higher stage there was a significantly higher mortality and a trend towards increased local recurrence.
Increased tumour sizes on imaging was associated with a trend towards increased mortality in accordance with the work of Hayes et al. [20] and other published series.
Over time there was considerable heterogeneity in the treatment regimes seen. This was probably as a result of the introduction and improvement of chemotherapy and the fact that little evidence existed regarding the best use of radiotherapy or surgery.
It is interesting to note the difference in incidence between the number of tumours diagnosed in the first 20 years of the registry when compared to the second 20 years (six versus 13 cases). It is not known if this is as a result of a genuine increase in the incidence of these tumours. From 1975 to 1999 the National Cancer Registry has collected information on cases of Ewing's sarcoma in children (0-14 years). [21] During this period 61 cases were recorded in total. Over the same period only 49 cases of Ewing's sarcoma were documented in the Scottish Bone Tumour Registry, suggesting that some of the differences observed in the incidence of Ewing's sarcoma during the 40 year period may be related to incomplete registry. Similar statistics for adults are not available for Ewing's sarcoma in isolation.
The small numbers in this study preclude any meaningful comparison between patients treated with adjuvant radiotherapy or surgery following chemotherapy, although there were no obvious differences between the groups in terms of overall survival. This concurs with the data from the CESS-86 study which found no differences in survival between patients treated with surgery or radiotherapy for localised disease [6, 7] . Surgery was found to be superior to radiotherapy in terms of local recurrence, however (11 vs. 20%), with the reverse being the case for metastasis. The most common site of Ewing's in the upper limb is the proximal humerus. Forequarter amputation clearly has far-reaching functional consequences, so a number of limb-sparing surgical strategies have been devised. These involve humeral resection and replacement with either a modular endoprosthesis (Figure 1) or a bulk allograft. If the most proximal and distal segments of the humerus can be preserved then a vascularised autograft is also a possibility. While these have produced good results in terms of elbow, forearm and hand function, the results at the shoulder were generally poor. [22] [23] [24] Allografts suffer a high failure rate, while endoprostheses can suffer from painful subacromial impingement secondary to deltoid resection, rotator cuff dysfunction and proximal migration of the prosthesis. Frequently the shoulder ends up stiff.
Radiotherapy offers an alternative treatment to surgery, although it also has its problems. Acutely this may mean skin breakdown or lymphoedema. In the long term, radiotherapy may result in tissue atrophy, fibrosis and muscle contracture, pathological fracture or second neoplasm. In addition radiographs and bone scans can continue to be abnormal for many years following treatment hindering the interpretation of local recurrence. Functional outcome in the upper limb does appear to be better, however [25] . There were no cases of second malignancies in this series. This may due to the relatively short follow-up, with many of the cases having being diagnosed in the last 10 years or the fact that the risk of a second malignancy has been shown to be quite low at 4.7% after 15 years [26] .
In conclusion, although the biological behaviour of Ewing's tumours of the upper extremity is similar to Ewing's found in other regions of the body and the presenting symptoms and examination findings are comparable to previous studies, far more upper limb tumours appear to be palpable at the time of presentation. Furthermore, patient delay makes the largest contribution to diagnostic delay and may affect the Enneking stage at presentation. A higher Enneking stage at presentation was found to have a significant effect on survival. The development of an algorithm to alert primary physicians to important worrying features such as swelling may be of value in the upper limb. The question of whether radiotherapy or surgery in addition to chemotherapy is superior in terms of survival remains to be answered. In current practice surgery still seems to be the preferred modality of choice for the control of localised Ewing's tumours.
